Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis

被引：0
|
作者：
K Yoshizaki
N Nishimoto
N Miyasaka
K Yamamoto
S Kawai
T Takeuchi
T Kishimoto
机构：
[1] Osaka University,Department of Medical Science I, School of Health and Sport Sciences
[2] Tokyo Medical and Dental University,School of Medicine
[3] University of Tokyo,Graduate School of Medicine
[4] St Marianna University of Medicine,undefined
[5] Saitama Medical Center/School,undefined
[6] Osaka University,undefined
来源：
Arthritis Res Ther | / 5卷
关键词：
Rheumatoid Arthritis; Rheumatoid Arthritis Patient; Amyloidosis; Thrombocytosis; Active Rheumatoid Arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
    Yoshizaki, K
    Nishimoto, N
    Miyasaka, N
    Yamamoto, K
    Kawai, S
    Takeuchi, T
    Kishimoto, T
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S42 - S42
  • [2] IL-6 and IL-21 in Rheumatoid Arthritis
    Carbone, Gustavo
    Wilson, Augusta
    Diehl, Sean
    Bunn, Janice
    Cooper, Sheldon
    Rincon, Mercedes
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S505 - S505
  • [3] Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?
    Ali Berkant Avci
    Eugen Feist
    Gerd Rüdiger Burmester
    BioDrugs, 2018, 32 : 531 - 546
  • [4] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Kazuyuki Yoshizaki
    Norihiro Nishimoto
    Masahiro Mihara
    Tadamitsu Kishimoto
    Springer Seminars in Immunopathology, 1998, 20 : 247 - 259
  • [5] Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci, Ali Berkant
    Feist, Eugen
    Burmester, Gerd Ruediger
    BIODRUGS, 2018, 32 (06) : 531 - 546
  • [6] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Yoshizaki, K
    Nishimoto, N
    Mihara, M
    Kishimoto, T
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1998, 20 (1-2): : 247 - 259
  • [7] EFFECTS OF IL-6 RECEPTOR INHIBITION THERAPY ON THE SERUM LEVELS OF IL-33 AND IL-6 IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Choi, I. A.
    Lee, S. J.
    Park, W.
    Park, S. H.
    Shim, S. -C.
    Baek, H. J.
    Yoo, D. -H.
    Kim, H. A.
    Lee, S. K.
    Lee, Y. J.
    Park, Y. E.
    Cha, H. -S.
    Lee, E. Y.
    Lee, E. B.
    Song, Y. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 456 - 456
  • [8] The value of blocking IL-6 outside of rheumatoid arthritis: current perspective
    Murakami, Miho
    Nishimoto, Norihiro
    CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (03) : 273 - 277
  • [9] Interleukin 6 (IL-6) signalling in rheumatoid arthritis
    Carty, SM
    Nowell, MA
    Goodfellow, RM
    Topley, N
    Jones, SA
    Williams, BD
    Williams, AS
    RHEUMATOLOGY, 2005, 44 : I38 - I38
  • [10] Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?
    Ali Berkant Avci
    Eugen Feist
    Gerd R. Burmester
    BioDrugs, 2024, 38 : 61 - 71
12345